Previous 10 | Next 10 |
Clearside Biomedical, Inc. (CLSD) Q1 2019 Earnings Conference Call May 08, 2019, 08:30 AM ET Company Participants Jenny Kobin - IR George Lasezkay - Interim CEO Thomas Ciulla - Chief Medical Officer Brion Raymond - Chief Commercial Officer Charlie Deignan - CFO Conference ...
Clearside Biomedical (NASDAQ: CLSD ): Q1 GAAP EPS of -$0.45 beats by $0.02. More news on: Clearside Biomedical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Scientific Presentations Support Broad Applicability of Clearside Delivery Platform - - XIPERE ™ under review for October 19, 2019 PDUFA Date - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 08, 2019 (GLOBE NEWSWIRE) -- ...
- SCS injection platform continues to be well-received by the medical community - - Suprachoroidal administration may offer targeted delivery of gene therapies without risks of vitrectomy and subretinal surgery - ALPHARETTA, Ga., May 01, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedica...
Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...
ALPHARETTA, Ga., April 25, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its first quarter 2019 financial resu...
Noteworthy events during the week of April 21 - 27 for healthcare investors. More news on: Galmed Pharmaceuticals Ltd., Horizon Pharma plc, Concert Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
ALPHARETTA, Ga., April 18, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple presentations will be made o...
Clearside Biomedical (NASDAQ: CLSD ) appoints George Lasezkay, Pharm.D., J.D. as Interim Chief Executive Officer (CEO), effective immediately. More news on: Clearside Biomedical, Inc., Healthcare stocks news, Stocks on the move, Read more ...
ALPHARETTA, Ga., April 02, 2019 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that Daniel H. White, President and Chief ...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...